Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects - The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Overview 7 Therapeutics Development 8 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Stage of Development 8 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Therapy Area 9 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Indication 10 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Companies 13 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Universities/Institutes 15 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 23 Amitech Therapeutic Solutions, Inc. 23 Basilea Pharmaceutica Ltd 24 CBT Pharmaceuticals Inc 25 Chugai Pharmaceutical Co Ltd 26 Hanmi Pharmaceuticals Co Ltd 27 Millennium Pharmaceuticals Inc 28 Novartis AG 29 Redx Pharma Plc 30 Sirnaomics Inc 31 VG Life Sciences Inc 32 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles 33 BAL-3833 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 CBT-102 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 DCBCI-0902 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 FYA-1001 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 HM-95573 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 hydroxychloroquine + sorafenib tosylate - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 LXH-254 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 RG-7304 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Small Molecules to Inhibit Raf Kinases for Oncology - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 STP-503 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 TAK-580 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 TEW-0201 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Projects 51 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products 52 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Featured News & Press Releases 53 Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO 53 Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting 53 Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting 54 Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 54 Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment 55 Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study 55 Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study 56 Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study 57 Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association; 58 Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study 59 Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine 59 Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib 60 Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer 60 Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors 62 Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Amitech Therapeutic Solutions, Inc., H2 2016 23 Pipeline by Basilea Pharmaceutica Ltd, H2 2016 24 Pipeline by CBT Pharmaceuticals Inc, H2 2016 25 Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 26 Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 27 Pipeline by Millennium Pharmaceuticals Inc, H2 2016 28 Pipeline by Novartis AG, H2 2016 29 Pipeline by Redx Pharma Plc, H2 2016 30 Pipeline by Sirnaomics Inc, H2 2016 31 Pipeline by VG Life Sciences Inc, H2 2016 32 Dormant Projects, H2 2016 51 Discontinued Products, H2 2016 52" "List of Figures
Number of Products under Development for, H2 2016 8 Number of Products under Development by Top 10 Indication, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Actions, H2 2016 18 Number of Products by Routes of Administration, H2 2016 19 Number of Products by Stage and Routes of Administration, H2 2016 19 Number of Products by Molecule Types, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
